These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

539 related items for PubMed ID: 17920284

  • 1. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
    Buck K, Ferger B.
    Neurobiol Dis; 2008 Feb; 29(2):210-20. PubMed ID: 17920284
    [Abstract] [Full Text] [Related]

  • 2. Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
    Buck K, Ferger B.
    Neuroscience; 2009 Mar 03; 159(1):16-20. PubMed ID: 19146929
    [Abstract] [Full Text] [Related]

  • 3. The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
    Buck K, Voehringer P, Ferger B.
    J Neurochem; 2010 Jan 03; 112(2):444-52. PubMed ID: 19895663
    [Abstract] [Full Text] [Related]

  • 4. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
    Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA.
    J Neurochem; 2006 Mar 03; 96(6):1718-27. PubMed ID: 16539687
    [Abstract] [Full Text] [Related]

  • 5. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA.
    J Neurochem; 2010 Mar 03; 112(6):1465-76. PubMed ID: 20050978
    [Abstract] [Full Text] [Related]

  • 6. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
    Silva MA, Mattern C, Häcker R, Tomaz C, Huston JP, Schwarting RK.
    Synapse; 1997 Dec 03; 27(4):294-302. PubMed ID: 9372552
    [Abstract] [Full Text] [Related]

  • 7. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.
    Meissner W, Ravenscroft P, Reese R, Harnack D, Morgenstern R, Kupsch A, Klitgaard H, Bioulac B, Gross CE, Bezard E, Boraud T.
    Neurobiol Dis; 2006 Jun 03; 22(3):586-98. PubMed ID: 16531050
    [Abstract] [Full Text] [Related]

  • 8. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.
    Cenci MA, Lee CS, Björklund A.
    Eur J Neurosci; 1998 Aug 03; 10(8):2694-706. PubMed ID: 9767399
    [Abstract] [Full Text] [Related]

  • 9. L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase.
    Shimamura M, Shimizu M, Yagami T, Funabashi T, Kimura F, Kuroiwa Y, Misu Y, Goshima Y.
    Neuropharmacology; 2006 Jun 03; 50(8):909-16. PubMed ID: 16504219
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
    Yin LL, Geng XC, Zhu XZ.
    Brain Res Bull; 2011 Nov 25; 86(5-6):367-72. PubMed ID: 21963945
    [Abstract] [Full Text] [Related]

  • 14. Site-specific action of L-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic L-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats.
    Buck K, Voehringer P, Ferger B.
    Neuroscience; 2010 Mar 17; 166(2):355-8. PubMed ID: 20026252
    [Abstract] [Full Text] [Related]

  • 15. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
    Johansson PA, Andersson M, Andersson KE, Cenci MA.
    Neurobiol Dis; 2001 Apr 17; 8(2):220-39. PubMed ID: 11300719
    [Abstract] [Full Text] [Related]

  • 16. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C, Cenci MA, Crossman AR, Ravenscroft P.
    J Neurochem; 2010 Jul 17; 114(2):499-511. PubMed ID: 20456008
    [Abstract] [Full Text] [Related]

  • 17. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
    Treseder SA, Rose S, Jenner P.
    Eur J Neurosci; 2001 Jan 17; 13(1):162-70. PubMed ID: 11135014
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
    Picconi B, Paillé V, Ghiglieri V, Bagetta V, Barone I, Lindgren HS, Bernardi G, Angela Cenci M, Calabresi P.
    Neurobiol Dis; 2008 Feb 17; 29(2):327-35. PubMed ID: 17997101
    [Abstract] [Full Text] [Related]

  • 20. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N, Martín AB, Mendialdua A, Moratalla R.
    Biol Psychiatry; 2006 Jan 01; 59(1):64-74. PubMed ID: 16139809
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.